ReviewJournal of diabetes and metabolic disorders2025
Semaglutide - properties, action and chromatographic analysis.
Review in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Beyond GLP-1 Agonists: Plant-Derived Bioactive Compounds as Adjunctive Strategies for Obesity Management.Nutrients · 2026Review
- Semaglutide from Bench to Bedside: The Experimental Journey Towards a Transformative Therapy for Diabetes, Obesity and Metabolic Liver Disorders.Medical sciences (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This review assessed the selected information on semaglutide's activity, its potential for the treatment of various diseases, and its pharmacokinetics. It is intended as a guide for future research. Chromatographic procedures used for the determination of semaglutide in various biological samples were also reviewed. Methods: A comprehensive review of the literature was conducted by searching scientific databases including PubMed, Scopus, Web of Science, and Google Scholar. The search was performed using keywords such as diabetic, type of diabetics, impact of diabetic glucagon-like peptide, DPP-4 inhibitors, GLP-1 agonists, semaglutide and weight loss, semaglutide and obesity, semaglutide and diabetic retinopathy, semalutide and mood, semaglutide and mood disorder, semaglutide and fertility, semaglutide and thyroid, semaglutide and inflammation, semaglutide and cardiovascular system, semaglutide and imapct on heart, semaglutide and neuroprotection, semaglutide and pancreatitis, safety of semaglutide, semaglutide and side effects, semaglutide and contraindication, and semaglutide analysis by liquid chromatography. Results: Semaglutide is the most potent glucose-lowering glucagon-like peptide (GLP-1) analogue and is widely used in the treatment of type 2 diabetes. Semaglutide increases the secretion of insulin from pancreatic β-cells and supresses glucagon release from pancreatic α-cells. Due to its effects on appetite regulation, it is also used to treat obesity in many countries. However, due to the slimming properties of the drug, semaglutide is often abused by non-diabetics, non-obese individuals, and young people. Recently, numerous investigations have been conducted to better understand the mechanism of action, as well as the advantages and disadvantages of using semaglutide. It is also very important to develop sensitive and accurate methods for detecting this drug in various biological samples collected from patients. Conclusion: Semaglutide is increasingly used of for the treatment of type 2 diabetes; however, its misuse for weight loss is also increasing. Further research is required to confirm the benefits of using semaglutide and to optimize treatment strategies for diverse patient populations.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.